Interpace Diagnostics Group (NASDAQ:IDXG) Shares Pass Above 50-Day Moving Average of $0.73

Interpace Diagnostics Group Inc (NASDAQ:IDXG)’s stock price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.73 and traded as high as $0.95. Interpace Diagnostics Group shares last traded at $0.94, with a volume of 13,119 shares traded.

Separately, HC Wainwright set a $4.00 target price on DURECT and gave the stock a “buy” rating in a research report on Friday. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $2.81.

The company has a market cap of $31.86 million, a P/E ratio of -2.16 and a beta of 2.20. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.26 and a quick ratio of 2.26. The company’s 50-day simple moving average is $0.73.

Interpace Diagnostics Group (NASDAQ:IDXG) last announced its quarterly earnings results on Monday, May 13th. The business services provider reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03). The company had revenue of $6.01 million during the quarter, compared to analysts’ expectations of $6.10 million. Interpace Diagnostics Group had a negative net margin of 53.75% and a negative return on equity of 34.69%. Sell-side analysts forecast that Interpace Diagnostics Group Inc will post -0.3 EPS for the current fiscal year.

A hedge fund recently raised its stake in Interpace Diagnostics Group stock. Perkins Capital Management Inc. increased its stake in Interpace Diagnostics Group Inc (NASDAQ:IDXG) by 86.4% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,922,250 shares of the business services provider’s stock after purchasing an additional 891,250 shares during the quarter. Perkins Capital Management Inc. owned about 5.05% of Interpace Diagnostics Group worth $1,538,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.81% of the company’s stock.

About Interpace Diagnostics Group (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.

Featured Story: What is the Dow Jones Industrial Average (DJIA)?

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit